CO4 Overview of Recent Systematic Literature Reviews on Glucagon-like Peptide-1 Receptor Agonists for Weight Loss in Adults with Obesity
The global prevalence of obesity has drastically increased over the past three decades, increasing the risk of obesity-related morbidity and premature mortality. Lifestyle/behavioral interventions for weight loss have had limited success. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are emerging as highly effective anti-obesity medications (AOMs). This research aims to identify key trends in systematic literature reviews (SLRs) on GLP-1 RAs in adults with obesity. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: K.E. Smoyer, L. Moubarak, S. Singh, S. Kandola Source Type: research
CO6 Teduglutide for Treating Short-Bowel Syndrome in Adults: A Meta-Analysis of Real-World Evidence Compared to Clinical Trial Data
Teduglutide is a treatment that allows patients with short bowel syndrome and type 3 intestinal failure (SBS- IF) to reduce their dependence on intravenous nutrition and fluids (parenteral support; PS). A pivotal randomized controlled trial (RCT) of teduglutide showed 63% of patients experienced a ≥20% reduction in weekly PS volume at 24 weeks. Individual real-world evidence (RWE) studies have reported greater and more rapid PS reductions than clinical trials, but whether this is a general trend is unknown. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: J. Eaton, R. Harvey, P. Cain, A. Dallongeville, S. Campbell-Hill Source Type: research
CO9 Post-Discharge Mortality in Patients with Mental Illness Hospitalized Compulsorily in Accordance with the Provisions of Article 29 of the Japanese Mental Health and Welfare Law
The objective of this study is to examine the post-discharge mortality risk in patients with severe mental illness who were hospitalized compulsorily in accordance with the provisions of Article 29 of the Japanese Mental Health and Welfare Law. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: A. Inagaki, H. Seto, T. Shimada, T. Otsuka, H. Iwanaga, K. Nakanishi, H. Nakamura, J. Watanabe, E. Kizaki, M. Tomita, T. Yokoshima, E. Okuno, Y. Kishi, J. Ota, A. Yoshizumi Source Type: research
CO10 A Matching-Adjusted Indirect Comparison of the Efficacy of Bimekizumab and Secukinumab at 52 Weeks for the Treatment of Psoriatic Arthritis
To compare the efficacy of bimekizumab 160mg and secukinumab 150-mg (SEC150) and 300-mg (SEC300) at 52 weeks (Wk52) for the treatment of psoriatic arthritis (PsA) using matching-adjusted indirect comparisons (MAICs). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: P.J. Mease, R.B. Warren, P. Nash, J.M. Grouin, D. Willems, V. Taieb, J. Eells, I. McInnes Source Type: research
CO11 Medication Adherence in Osteoporosis Treatments and the Impact in Patients' Quality of Life
To investigate the degree of adherence to medication in women with osteoporosis and the impact in patient ’s quality of life (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: P. Tsaousis, P. Theodorou, M. Hatzikou Source Type: research
CO12 5 Years of Real-World Data on the Use of Cladribine Tablets for the Treatments of Multiple Sclerosis in Portugal
To present real-world data from a patient registry of multiple sclerosis (MS) patients being treated with cladribine tablets (CT) since its launch in Portugal (PT). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Ribeiro, D. Pinto Source Type: research
CO14 Identification & Use of Prognostic Variables (PVs)/Treatment Effect Modifiers (TEMs) in Indirect Treatment Comparisons (ITCs) By Systematic Literature Review (SLR): Case Study of Chimeric Antigen Receptor (CAR) T-Cell Therapies
ITCs estimate relative treatment effects not compared in head-to-head trials. According to the assumption of transitivity, trials must be comparable on factors including PVs/TEMs; however, these are not always consistently identified. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: C.D. Igbelina, R. Campden, S. Grieve, D. Thakur Source Type: research
CO15 Clinical Outcomes of Patients with Relapsed/Refractory Large B-Cell Lymphoma Receiving Second-Line Therapy in England: A Multicenter, Retrospective, Real-World Study
This study examines the impact of ASCT-eligibility on survival outcomes in R/R LBCL. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: C.P. Fox, F. Toron, E. Tyas, M. Cooper, J. Richards, P. Williams Source Type: research
CO16 Effect of Daratumumab on Pneumonia in Patients with Multiple Myeloma Using Population Based Real-World Data
Infections are major causes of morbidity and mortality in multiple myeloma (MM). Daratumumab improved patient outcomes but increased the risk of infectious complications, including pneumonia. The aim of this study was to identify the effect of daratumumab on pneumonia using real-world data. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: Y. Kim, K.W. Kang, H.S. Suh Source Type: research
CO17 How to Assess Nationwide Population-Based Clinical Benefit of Treatments Using Public Information? Immunotherapies Case Study
The objectives are to present a methodology to assess popul ation-based clinical benefit of treatments. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: V. Grumberg, F.E. Cotte, A.F. Gaudin, I. Borget Source Type: research
CO19 Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Atezolizumab in combination with carboplatin-etoposide is indicated for the first-line treatment of extensive-stage small-cell lung cancer(ES-SCLC). The aim of our study is to analyze the effectiveness and safety of atezolizumab combined with chemotherapy in ES-SCLC in a tertiary hospital, and to compare with the pivotal IMpower133 trial. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Dom ínguez, I. Carrión Madroñal, J.A. Marcos Rodríguez, M. Valera-Rubio Source Type: research
CO20 Use of Inpatient Systemic Chemotherapy and/or Radiotherapy and Related Predictive Factors for Metastatic Urothelial Cancer (mUC): Findings from a Retrospective Observational Study in a Clinical Practice Setting in Italy
This study describes the treatment rate and related predictive factors, demographics, and clinical characteristics of patients with mUC who received systemic chemotherapy and/or radiotherapy (or not), in the inpatient setting in Italy. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Kearney, A. Thompson, M. Kirker, N. Gharibian, N. Costa, M. Furegato, C. Pacheco, S. Issa, P. Sciattella, M. Scortichini, F.S. Mennini Source Type: research
CO21 Matching Adjusted Indirect Comparison (MAIC) of Selpercatinib Vs Cabozantinib in RET Mutation-Positive Advanced Medullary Thyroid Cancer (MTC)
To estimate comparative effectiveness, in terms of objective response rate (ORR), progression free and overall survival (PFS, OS) using unanchored MAIC of single-arm LIBRETTO-001 (selpercatinib) and EXAM trials (cabozantinib vs placebo) in advanced/metastatic RET mutation-positive MTC. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M.H. Jen, U. Kiiskinen, M. Khanal, Y. Han, L. Hess, W. Tian, A. Vickers Source Type: research
CO22 Healthcare Resource Utilization (HCRU), Effectiveness and Safety of Trifluridine/Tipiracil in Treatment of Refractory Metastatic Colorectal Cancer in a Portuguese Comprehensive Cancer Center (PCCC)
This study aim to assessed HCRU and FDT-TPI clinical outcomes in a real-world(RW) setting. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: P. Redondo, J. Brito da Silva, C. de Paiva Agostinho, R. Banha, A.S. Silva, C. Faustino, D. Marques Source Type: research
CO23 How Immunotherapies Have Altered the Future of Cancer Treatment: Patients Living Longer, Healthier Lives
Since entering the market immunotherapies have led to a paradigm shift in mortality rates for patients with melanoma resulting in an overall improvement in survival and quality of life. This review maps the shift by comparing changes in patient outcomes alongside the frequency of positive HTA decisions for immunotherapy treatments in the UK and Australia between 2019 and 2023. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S. Borges, D. Shaw, A. Meunier, J. Farrington Source Type: research
